Castle Biosciences, Inc.

CSTL

$32.65

-2.30%

2026-09-03 16:00:00 EDT-$0.77

Healthcare

Medical - Diagnostics & Research

NASDAQ

Active Trading

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing ...

Price Action of CSTL

$32.65

-2.30%-$0.77

High—

Low—

52W High-26.3%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

Castle Biosciences, Inc. (Nasdaq: CSTL) is a leading molecular diagnostics company dedicated to improving health through innovative tests that guide patient care. Founded in 2007 by Derek J. Maetzold, who serves as President and CEO, the company is headquartered in Friendswood, Texas, with laboratory facilities in Phoenix, Arizona, and Pittsburgh, ...Castle Biosciences, Inc. (Nasdaq: CSTL) is a leading molecular diagnostics company dedicated to improving health through innovative tests that guide patient care. Founded in 2007 by Derek J. Maetzold, who serves as President and CEO, the company is headquartered in Friendswood, Texas, with laboratory facilities in Phoenix, Arizona, and Pittsburgh, Pennsylvania. Castle specializes in proprietary laboratory-developed tests that provide personalized, clinically actionable information to healthcare providers and patients, primarily in the field of dermatological oncology. Core products include DecisionDx-Melanoma, a multi-gene expression profile (GEP) assay that assesses the risk of metastasis for invasive cutaneous melanoma; DecisionDx-UM for uveal melanoma; DecisionDx-SCC for squamous cell carcinoma; and DecisionDx DiffDx-Melanoma and myPath Melanoma for aiding in the diagnosis of ambiguous pigmented lesions. These tests help guide treatment decisions, reducing unnecessary procedures and improving patient outcomes. The company's business model focuses on commercial-stage diagnostics, generating revenue through test sales. As of the latest data, Castle employs 883 people and has a market capitalization of approximately $978 million. Financially, it shows a gross profit margin of 77.3% but has been operating at a loss, with a net profit margin of -5.4% and negative EBITDA. However, it maintains a strong balance sheet with a current ratio of 6.036 and minimal debt, and invests heavily in R&D (15.5% of revenue) and sales/marketing (68.2% of revenue). Key leadership includes founder Derek Maetzold, who has been recognized with a CEO of the Year award. The company went public in July 2019 and trades on the NASDAQ Global Market. Castle aims to transform disease management by providing personalized, clinically actionable information, with a mission to improve health through innovative tests.ExpandCollapse

Founded

2007

Employees

1002

CEO

Derek J. Maetzold

Full Name

Castle Biosciences, Inc.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

ROE

-4.15%

Market Cap

$1.00B

Current Ratio

6.04

WACC

8.93%

ROIC

-3.82%

Contact Information

https://castlebiosciences.com

866 788 9007

1500 W. Parkwood Ave, Friendswood, TX 77546

Key Metrics of CSTL

Snapshot

Latest / TTM · 6 periods

Market Cap

$997.44M

ROCE

-6.4%

EV / EBITDA

-300.36x

+2.0% YoY

FCF Yield

-0.0%

-2.6% YoY

Cash Conversion Cycle

53.5d

Current Ratio

6.04

Quick take

TTM —

Positive CCC

Financial Highlights of CSTL

Profitability trend

Latest / TTM · 6 periods

Gross Margin

77.3%

Net Margin

-5.4%

P/E Ratio

-49.51x

n/a

Debt / Equity

0.08

n/a

Current Ratio

6.04

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of CSTL

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.36 · Revenue $92.13M · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.36 · Revenue $93.68M · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.27 · Revenue $372.59M · 6 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.42 · Revenue $95.47M · 3 analysts

Recent history

Jul 30, 2026
Q2 FY2026 · Results reported
EPS $-0.07 · Revenue $103.55M
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $-0.49 · Revenue $83.68M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-0.83 · Revenue $344.23M
View filing
Nov 3, 2025
Q3 FY2025 · Results reported
EPS $-0.02 · Revenue $83.04M
View filing
Aug 4, 2025
Q2 FY2025 · Results reported
EPS $0.15 · Revenue $86.19M
View filing
May 5, 2025
Q1 FY2025 · Results reported
EPS $-0.90 · Revenue $87.99M
View filing

Financial Statements of CSTL

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$344.2M	+3.7%	+23.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-24.2M	-232.4%	+85.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+79.4%	-3.1%	+2.2%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-12.4%	-576.3%	+86.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-7.0%	-227.7%	+88.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$28.3M	-22.5%	+118.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+8.2%	-25.2%	+115.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	7.8%	+35.6%	-2.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	5.26x	-27.9%	-10.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$578.6M	+8.9%	+2.4%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.83 vs -1.04	+20.1%	-0.07 vs -0.41	+82.8%
Revenue Surprise	$344.2M vs $336.2M	+2.4%	$103.5M vs $86.2M	+20.1%

Insider Transactions of CSTL

Acquisitions (A)

Since Aug 28, 2026

Disposals (D)

Since Aug 28, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Oelschlager Kristen M	officer: Chief Operating Officer	Common Stock	A	4,152	$3.38
Sep 1, 2026	Oelschlager Kristen M	officer: Chief Operating Officer	Common Stock	D	3,952	$33.36
Sep 1, 2026	Oelschlager Kristen M	officer: Chief Operating Officer	Common Stock	D	200	$34.02
Sep 1, 2026	Oelschlager Kristen M	officer: Chief Operating Officer	Stock option (right to buy)	D	4,152	$3.38
Aug 31, 2026	Juvenal Tobin W	officer: Chief Commercial Officer	Common Stock	D	1,730	$32.81

Earnings Call Transcript of CSTL

1 transcript segments

Q2 2026

Unknown Speaker

Operator : Good afternoon, and welcome to the Castle Biosciences Second Quarter 2026 Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session. I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Please go ahead. Camilla Zuckero : Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences Second Quarter 2026 Results Conference Call. Joining me today are Castle's Founder, President and Chief Executive Officer, Derek Maetzold; and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, July 30, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately 3 weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets, statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue and the impact of our investments in growth initiatives, including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward-looking statements. Please refer to the risk factors in our most recent SEC filings for more information. These forward-looking statements speak only as of today, and we assume no obligation to update or revise these forward-looking statements as circumstances change. In addition, some of the information discussed today includes non-GAAP financial measures such as adjusted revenue, adjusted gross margin and adjusted EBITDA that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. I will now turn the call over to Derek. Derek Maetzold : Thank you, Camilla, and good afternoon, everyone. What a great quarter. Our team across all areas of Castle did a phenomenal job in executing on our growth plans and pulling it through the business, including revenue on the top line in evidence development and clinical research. Thanks to the efforts by our team and …

Leadership Team of CSTL

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Derek J. Maetzold	Founder, Chief Executive Officer, President & Director	USD 1,809,563	Male	1962	Active
Frank Stokes	Chief Financial Officer & Treasurer	USD 1,001,919	Male	1970	Active
Kristen Oelschlager	Chief Operating Officer	USD 944,652	Female	1969	Active
Tobin W. Juvenal	Chief Commercial Officer	USD 944,652	Male	1961	Active
Jay Braxton	Vice President of Marketing & Brand Manager of Uveal Melanoma (UM)	—	—	—	Active
Camilla Zuckero	Vice President of Investor Relations & Corporate Affairs	—	Female	—	Active
Trisha Poteet	Senior VP of Clinical Services & Manufacturing Operations	—	Female	—	Active
Keli Greenberg	Vice President of Human Resources	—	Female	—	Active
Kevin Doman	Vice President of Sales	—	Male	—	Active
Matthew Goldberg	Senior Vice President of Medical	—	—	—	Active

Recent News of CSTL

Zacks Investment Research8/28/2026Neutral

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research8/25/2026Neutral

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PRNewsWire8/20/2026Neutral

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.

PRNewsWire8/17/2026Neutral

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.

MarketBeat8/13/2026Neutral

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.

Historical Employee Count of CSTL

Current

883

Change

+16.03%

Minimum

342

Maximum

883

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	883	10-K	Feb 26, 2026	View
Dec 31, 2024	761	10-K	Feb 27, 2025	View
Dec 31, 2023	610	10-K	Feb 28, 2024	View
Dec 31, 2022	542	10-K	Feb 28, 2023	View
Dec 31, 2021	342	10-K	Feb 28, 2022	View

Related stocksMedical - Diagnostics & Research

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Castle Biosciences, Inc.